Third Quarter Report (PDF)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Telaprevir (Incivek)
© Hepatitis C Online PDF created September 25, 2021, 4:19 pm Telaprevir (Incivek) Discontinued. This treatment has been discontinued. Table of Contents Telaprevir Incivek Summary Drug Summary Adverse Effects Class and Mechanism Manufacturer for United States FDA Status Indications Dosing Clinical Use Cost and Medication Access Resistance Key Drug Interactions Full Prescribing Information Figures Drug Summary Although telaprevir was a promising direct-acting antiviral agent that had impact in the hepatitis C treatment field during 2011 to 2013, it was subsequently replaced by newer direct-acting antiviral agents that were more effective, better tolerated, and more convenient. Based on the dwindling role of telaprevir after newer direct-acting antiviral agents were approved, Vertex pharmaceuticals discontinued the sales and distribution of telaprevir in the United States in October 2014. Telaprevir does have some current importance since persons who previously failed a telaprevir-based regimen may have developed resistant associated variants, which could potentially impact subsequent therapy. Adverse Effects The most significant adverse effects reported in the main registration trials and in post-marketing experience were rash, anorectal complaints, and anemia. When comparing triple therapy of telaprevir, peginterferon, and ribavirin with dual therapy of peginterferon and ribavirin alone significant differences were noted with rash (56% versus 34%), anemia (36% versus 17%), and anorectal complaints that include anorectal discomfort, anal pruritus, and hemorrhoids (29% versus 7%). In most cases, the rash that develops is eczematous or maculopapular in character and mild to moderate in severity; the rash is typically manageable with good skin care and topical emollients or corticosteroids. In some instances, however, telaprevir has caused serious skin Page 1/5 rashes, including Steven's Johnson Syndrome (SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis (TEN). -
ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021
ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 Company Ticker CUSIP Shares Market Value($) Weight(%) 1 TELADOC HEALTH INC TDOC 87918A105 3,937,797 531,208,815.30 6.99 2 EXACT SCIENCES CORP EXAS 30063P105 3,971,013 381,296,668.26 5.01 3 PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 13,696,148 350,347,465.84 4.61 4 VERTEX PHARMACEUTICALS INC VRTX 92532F100 1,722,281 316,228,014.41 4.16 5 FATE THERAPEUTICS INC FATE 31189P102 4,825,395 312,926,865.75 4.12 6 IONIS PHARMACEUTICALS INC IONS 462222100 8,572,965 310,341,333.00 4.08 7 REGENERON PHARMACEUTICALS REGN 75886F107 430,742 275,201,063.80 3.62 8 TWIST BIOSCIENCE CORP TWST 90184D100 2,237,350 250,829,308.50 3.30 9 TAKEDA PHARMACEUTIC-SP ADR TAK UN 874060205 13,592,076 229,570,163.64 3.02 10 ACCOLADE INC ACCD 00437E102 5,268,242 226,850,500.52 2.98 11 INTELLIA THERAPEUTICS INC NTLA 45826J105 1,508,421 224,965,907.94 2.96 12 VEEVA SYSTEMS INC-CLASS A VEEV 922475108 741,198 222,307,516.14 2.92 13 CAREDX INC CDNA 14167L103 3,433,475 220,978,451.00 2.91 14 CRISPR THERAPEUTICS AG CRSP H17182108 1,804,041 210,044,493.63 2.76 15 INCYTE CORP INCY 45337C102 2,893,385 199,643,565.00 2.63 16 INVITAE CORP NVTA 46185L103 6,059,066 182,135,523.96 2.40 17 ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 4,888,391 178,377,387.59 2.35 18 BEAM THERAPEUTICS INC BEAM 07373V105 1,849,698 175,110,909.66 2.30 19 SIGNIFY HEALTH INC -CLASS A SGFY 82671G100 8,107,683 160,937,507.55 2.12 20 UIPATH INC - CLASS A PATH 90364P105 2,955,628 155,761,595.60 2.05 21 CASTLE BIOSCIENCES INC CSTL 14843C105 2,130,211 -
Vertex Pharmaceuticals Global Medical Affairs Pharmd Fellowship Program 2020 Message from Global Medical Affairs Leadership
Vertex Pharmaceuticals Global Medical Affairs PharmD Fellowship Program 2020 Message from Global Medical Affairs Leadership Dear Candidates, Vertex Pharmaceuticals in collaboration with Northeastern University is privileged to host and expand the PharmD Fellowship Program. We are excited to work with our fellows as integral members of our team and facilitate in-depth exposure to a range of functional areas, offering them the critical opportunity to gain extensive experience in the biopharmaceutical industry. In addition to fostering each individual’s personal and professional growth, the program’s primary goal is to extend the visibility of valuable contributions that a Doctor of Pharmacy can bring to the pharmaceutical industry. At Vertex, our Global Medical Affairs fellows are highly encouraged to take on immersive projects, allowing them to work across departments with leaders in the industry. We advocate for them to partake in truly unique, impactful work that develops their skills, sparks curiosity, and drives the science. Vertex’s open and innovative culture allows the fellows to ask questions, challenge the status quo, and explore their interests across multiple expertise areas. As a pharmacist, I am extremely proud of the establishment of the Vertex PharmD Fellowship program in Global Medical Affairs and excited to welcome our future fellows. Vertex is an ideal place for fellows to start their professional career, and we are dedicated to the development of the next generation of pharmacist leaders in the biopharmaceutical industry. As Vertex continues to grow and evolve into a company in multiple disease areas, I am confident that our fellows will be an essential part of moving the needle to deliver on our commitment to patients. -
SCHEDULE of INVESTMENTS MID-CAP 1.5X STRATEGY FUND
SCHEDULE OF INVESTMENTS December 31, 2020 MID-CAP 1.5x STRATEGY FUND SHARES VALUE SHARES VALUE COMMON STOCKS† - 39.5% United Bankshares, Inc. 118 $ 3,823 Kinsale Capital Group, Inc. 19 3,802 FINANCIAL - 9.3% Highwoods Properties, Inc. REIT 95 3,765 Medical Properties Trust, Inc. REIT 489 $ 10,655 RLI Corp. 36 3,749 Brown & Brown, Inc. 215 10,193 Park Hotels & Resorts, Inc. REIT 215 3,687 Camden Property Trust REIT 89 8,893 Selective Insurance Group, Inc. 55 3,684 CyrusOne, Inc. REIT 110 8,047 Rayonier, Inc. REIT 125 3,673 Alleghany Corp. 13 7,848 Healthcare Realty Trust, Inc. REIT 124 3,670 RenaissanceRe Holdings Ltd. 46 7,628 Valley National Bancorp 369 3,598 Omega Healthcare Investors, Inc. REIT 207 7,518 Webster Financial Corp. 82 3,456 STORE Capital Corp. REIT 216 7,340 Bank OZK 110 3,440 Reinsurance Group of Physicians Realty Trust REIT 190 3,382 America, Inc. — Class A 62 7,186 PROG Holdings, Inc. 62 3,340 Eaton Vance Corp. 104 7,065 Hudson Pacific Properties, Inc. REIT 139 3,339 Jones Lang LaSalle, Inc.* 47 6,973 Sabra Health Care REIT, Inc. 189 3,283 Signature Bank 49 6,629 Alliance Data Systems Corp. 44 3,260 Lamar Advertising Co. — Class A REIT 79 6,574 Wintrust Financial Corp. 53 3,238 East West Bancorp, Inc. 129 6,541 CIT Group, Inc. 90 3,231 National Retail Properties, Inc. REIT 159 6,506 JBG SMITH Properties REIT 102 3,190 First Horizon National Corp. 507 6,469 Sterling Bancorp 177 3,183 SEI Investments Co. -
United States Securities and Exchange Commission Form
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2005 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS 000-19319 04-3039129 (State or other jurisdiction of (Commission File Number) (IRS Employer Identification incorporation) No.) 130 Waverly Street Cambridge, Massachusetts 02139 (Address of principal executive offices) (Zip Code) (617) 444-6100 Registrant’s telephone number, including area code: Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01. Other Events. On June 17, 2005, Vertex Pharmaceuticals Incorporated and Merck & Co., Inc. issued a joint press release that announced the initiation of an additional Phase I study with VX-680, a small molecule inhibitor of Aurora kinases. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01. -
Usef-I Q2 2021
Units Cost Market Value U.S. EQUITY FUND-I U.S. Equities 88.35% Domestic Common Stocks 10X GENOMICS INC 5,585 868,056 1,093,655 1ST SOURCE CORP 249 9,322 11,569 2U INC 301 10,632 12,543 3D SYSTEMS CORP 128 1,079 5,116 3M CO 11,516 2,040,779 2,287,423 A O SMITH CORP 6,897 407,294 496,998 AARON'S CO INC/THE 472 8,022 15,099 ABBOTT LABORATORIES 24,799 2,007,619 2,874,948 ABBVIE INC 17,604 1,588,697 1,982,915 ABERCROMBIE & FITCH CO 1,021 19,690 47,405 ABIOMED INC 9,158 2,800,138 2,858,303 ABM INDUSTRIES INC 1,126 40,076 49,938 ACACIA RESEARCH CORP 1,223 7,498 8,267 ACADEMY SPORTS & OUTDOORS INC 1,036 35,982 42,725 ACADIA HEALTHCARE CO INC 2,181 67,154 136,858 ACADIA REALTY TRUST 1,390 24,572 30,524 ACCO BRANDS CORP 1,709 11,329 14,749 ACI WORLDWIDE INC 6,138 169,838 227,965 ACTIVISION BLIZZARD INC 13,175 839,968 1,257,422 ACUITY BRANDS INC 1,404 132,535 262,590 ACUSHNET HOLDINGS CORP 466 15,677 23,020 ADAPTHEALTH CORP 1,320 39,475 36,181 ADAPTIVE BIOTECHNOLOGIES CORP 18,687 644,897 763,551 ADDUS HOMECARE CORP 148 13,034 12,912 ADOBE INC 5,047 1,447,216 2,955,725 ADT INC 3,049 22,268 32,899 ADTALEM GLOBAL EDUCATION INC 846 31,161 30,151 ADTRAN INC 892 10,257 18,420 ADVANCE AUTO PARTS INC 216 34,544 44,310 ADVANCED DRAINAGE SYSTEMS INC 12,295 298,154 1,433,228 ADVANCED MICRO DEVICES INC 14,280 895,664 1,341,320 ADVANSIX INC 674 15,459 20,126 ADVANTAGE SOLUTIONS INC 1,279 14,497 13,800 ADVERUM BIOTECHNOLOGIES INC 1,840 7,030 6,440 AECOM 5,145 227,453 325,781 AEGLEA BIOTHERAPEUTICS INC 287 1,770 1,998 AEMETIS INC 498 6,023 5,563 AERSALE CORP -
Wilmington Funds Holdings Template DRAFT
Wilmington Large-Cap Strategy Fund as of 5/31/2021 (Portfolio composition is subject to change) ISSUER NAME % OF ASSETS APPLE INC 4.97% MICROSOFT CORP 4.69% AMAZON.COM INC 3.45% FACEBOOK INC 1.99% ALPHABET INC 1.80% ALPHABET INC 1.77% BERKSHIRE HATHAWAY INC 1.48% JPMORGAN CHASE & CO 1.35% TESLA INC 1.20% JOHNSON & JOHNSON 1.12% UNITEDHEALTH GROUP INC 0.98% VISA INC 0.96% NVIDIA CORP 0.96% BANK OF AMERICA CORP 0.89% HOME DEPOT INC/THE 0.87% WALT DISNEY CO/THE 0.82% MASTERCARD INC 0.80% PAYPAL HOLDINGS INC 0.77% EXXON MOBIL CORP 0.68% PROCTER & GAMBLE CO/THE 0.67% COMCAST CORP 0.66% ADOBE INC 0.62% INTEL CORP 0.59% VERIZON COMMUNICATIONS INC 0.59% CISCO SYSTEMS INC 0.57% CHEVRON CORP 0.55% PFIZER INC 0.54% NETFLIX INC 0.54% AT&T INC 0.53% SALESFORCE.COM INC 0.53% ABBOTT LABORATORIES 0.51% ABBVIE INC 0.50% MERCK & CO INC 0.48% WELLS FARGO & CO 0.48% BROADCOM INC 0.47% THERMO FISHER SCIENTIFIC INC 0.47% ACCENTURE PLC 0.46% CITIGROUP INC 0.45% MCDONALD'S CORP 0.44% TEXAS INSTRUMENTS INC 0.44% COCA-COLA CO/THE 0.44% HONEYWELL INTERNATIONAL INC 0.44% LINDE PLC 0.43% MEDTRONIC PLC 0.43% NIKE INC 0.43% ELI LILLY & CO 0.42% PEPSICO INC 0.42% UNITED PARCEL SERVICE INC 0.41% WALMART INC 0.40% DANAHER CORP 0.40% UNION PACIFIC CORP 0.40% QUALCOMM INC 0.38% BRISTOL-MYERS SQUIBB CO 0.37% ORACLE CORP 0.37% LOWE'S COS INC 0.36% BLACKROCK INC 0.35% CATERPILLAR INC 0.35% AMGEN INC 0.35% BOEING CO/THE 0.35% MORGAN STANLEY 0.35% COSTCO WHOLESALE CORP 0.35% RAYTHEON TECHNOLOGIES CORP 0.34% STARBUCKS CORP 0.34% GOLDMAN SACHS GROUP INC/THE 0.34% GENERAL ELECTRIC -
GROW with US Essential Utilities, Inc
GROW WITH US Essential Utilities, Inc. 2021 Annual Meeting of Shareholders NYSE: WTRG 47998_EU_Proxy-21_Covers_4c_v6.indd 1 3/19/21 4:26 PM OUR KEY PILLARS Infrastructure We are committed to thoughtful and continuous investment in the infrastructure that delivers water and wastewater service and natural gas to our customers safely and reliably. Operations We are committed to responsibly leveraging our industry expertise, purchasing power, economies of scale and efficiencies and to operational excellence benefiting our customers and shareholders. Environment We take our role as a provider of water and natural gas very seriously, and we return wastewater safely back to the environment. We are committed to sustainable business practices that protect these valuable natural resources and work to ensure the environment is safeguarded for future generations. Safety We are committed to creating a culture that empowers employees to prioritize their safety and well-being and the safety of others above all else. We strive for safe treatment and delivery of water and gas to each customer we serve. 47998_EU_Proxy-21_Covers_4c_v6.indd 2 3/19/21 4:26 PM March 22, 2021 To Our Shareholders On behalf of your Board of Directors, I am pleased to invite you to attend the 2021 Annual Meeting of the Shareholders of Essential Utilities, Inc. to be held virtually on Wednesday, May 5, 2021. I’m sure you will agree that 2020 was a transformative year for the company, as well as the country. Just as the COVID-19 pandemic began to sweep the U.S. and the country started to shut down and begin social distancing, Essential completed our momentous acquisition of Peoples Natural Gas. -
Pax Large Cap Fund USD 7/31/2021 Port
Pax Large Cap Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight Microsoft Corporation 89,240,649.84 6.2 Apple Inc. 56,474,074.80 3.9 Alphabet Inc. Class A 45,168,406.39 3.1 Applied Materials, Inc. 40,802,748.42 2.8 United Parcel Service, Inc. Class B 40,145,031.68 2.8 Amazon.com, Inc. 40,024,252.52 2.8 Procter & Gamble Company 38,175,527.61 2.6 Alphabet Inc. Class C 37,288,542.96 2.6 T-Mobile US, Inc. 36,913,478.16 2.5 CVS Health Corporation 35,823,305.60 2.5 Bristol-Myers Squibb Company 35,683,263.33 2.5 Trane Technologies plc 34,492,144.83 2.4 Voya Financial, Inc. 34,364,677.20 2.4 Fiserv, Inc. 33,109,434.63 2.3 Medtronic Plc 32,631,060.24 2.2 Lowe's Companies, Inc. 32,345,328.78 2.2 JPMorgan Chase & Co. 31,275,786.80 2.2 salesforce.com, inc. 31,164,938.74 2.1 Aptiv PLC 30,049,685.00 2.1 Target Corporation 29,624,476.10 2.0 Becton, Dickinson and Company 29,334,525.00 2.0 Citizens Financial Group, Inc. 28,825,635.20 2.0 Merck & Co., Inc. 28,216,517.16 1.9 BlackRock, Inc. 28,142,268.01 1.9 Vertex Pharmaceuticals Incorporated 26,265,874.00 1.8 Lincoln National Corporation 25,842,318.84 1.8 Sysco Corporation 25,428,711.00 1.8 Equinix, Inc. -
PD2M Newsletter
PD2M Newsletter March 2020 Note from the Editor Our first issue of the PD2M Newsletter 2020 highlights two interesting topics: - Pharma 4.0: The term “Industry 4.0” was first used in Germany to incentivize modernization of manufacturing. The International Society for Pharmaceutical Engineering (ISPE) adapted it 2017 and the concept of “Pharma 4.0” was born. The Carla Luciani vision of highly efficient, vastly automated, self-driven manufacturing processes is extremely appealing to Pharmaceutical Discovery, practitioners. But separating hype from reality is important. Get Development and Manufacturing a feel of what is going on from Nima Yazdanpanah Forum, Newsletter Chair (Procegence), Shujauddin Changi (Vertex), Moiz Diwan (Abbvie), and Christopher Burcham (Eli Lilly) who reported RNA-Tx, Lilly Research Pharma 4.0 Highlights from the last AIChE Annual Meeting. Laboratories, Eli Lilly & Co. - Connect @ AIChE: Meet candidates in a poster session & reception at the 2020 AIChE Annual Meeting in San Francisco. If you are a graduate student/postdoc who are available for In this issue: employment by summer 2021 or you work in industry and want to meet new talent and grow connections, this is a great event Note from the Page 1 to do so. Learn everything you need to know here. Editor There is still more to come on PD2M programming and activities. Don’t Pharma 4.0 Page 2 miss future issues of the PD2M Newsletter. Highlights Connect @ AIChE Page 6 It is all about connectivity… 1 | Page Page | 1 Page | 1 PD2M Newsletter Pharma 4.0 Highlights from AIChE Annual Meeting 2019 The Pharma 4.0 paradigm, analogous to the The Pharma 4.0 was topic of two plenary sessions Industry 4.0, intends to utilize enabling technologies in the AIChE Annual meeting 2019 in Orlando, FL, in the pharmaceutical and biopharmaceutical held by PD2M and Next-Gen Manufacturing industries. -
U.S. Investor-Owned Electric Companies International Members Associate Members EEI the Edison Electric Institute, Is the Association That Represents All U.S
Members List U.S. Investor-Owned Electric Companies International Members Associate Members EEI The Edison Electric Institute, is the association that represents all U.S. investor-owned electric companies. Our members provide electricity for about 220 million Americans, and operate in all 50 states and the District of Columbia. As a whole, the electric power industry supports more than 7 million jobs in communities across the United States. In addition to our U.S. members, EEI has more than 65 international electric companies with operations in more than 90 countries, as International Members, and hundreds of industry suppliers and related organizations as Associate Members. Organized in 1933, EEI provides public policy leadership, strategic business intelligence, and essential conferences and forums. U.S. Energy Companies AES Corporation Entergy Corporation Otter Tail Corporation Dayton Power & Light Company Entergy Arkansas Otter Tail Power Company Indianapolis Power & Light Company Entergy Louisiana PG&E Corporation Alaska Power & Telephone Company Entergy Mississippi Pacific Gas & Electric Company ALLETE Entergy New Orleans Pinnacle West Capital Corporation Minnesota Power Entergy Texas Arizona Public Service Company Superior Water, Light and Power Company Evergy PNM Resources Alliant Energy Eversource Energy PNM Ameren Corporation Exelon Corporation TNMP Ameren Illinois Atlantic City Electric Portland General Electric Ameren Missouri BGE PPL Corporation American Electric Power ComEd PPL Electric Utilities AEP Ohio Delmarva Power LG&E -
2020 Annual Report
2020 Annual Report 1 THE GIRL SCOUT MISSION THE GIRL SCOUT LAW Girl Scouting builds girls of courage, I will do my best to be confidence, and character, honest and fair, who make the world a better place. friendly and helpful, considerate and caring, courageous and strong, and THE GIRL SCOUT PROMISE responsible for what I say and do, and to On my honor, I will try: respect myself and others, To serve God and my country, respect authority, To help people at all times, use resources wisely, And to live by the Girl Scout Law. make the world a better place, and be a sister to every Girl Scout. Annual Report Cover – The cover of the Annual Report this year represents the tale of two half years that we experienced in 2020 with color and a girl journey. The two half years are represented by the two Pantone colors of the year, Ultimate Gray and Illuminating Yellow. The gradient and movement of the two colors interacting with one another share how the year started out yellow, exciting and normal and moved into the gray with uncertainty and overwhelming change of the world around us. The girl’s journey ultimately reverts back to yellow as we take our new normal in stride and look into our future with resilience. 2 TABLE OF CONTENTS Executive Message 4 Take the Lead 22 Transformation Strategy 6 Thank you to our Donors 24 Program Accomplishments FY20 10 Board of Directors 30 Financial Report 20 Our Footprint 31 3 GIRL SCOUT LEADERSHIP EXPERIENCE (GSLE) IN ACTION: GIRL SCOUTS GIVING BACK DURING THE PANDEMIC Making masks for frontline healthcare workers Writing letters to isolated elderly people in retirement communities Organizing food and supply drives for increased at-risk population Staying connected while physically apart EXECUTIVE MESSAGE 4 Working Together to help create the next generation of female leaders.